Abstract
SMARCA4‐deficient thoracic sarcoma (SMARCA4‐DTS) is a recently recognized entity with undifferentiated rhabdoid morphology and mutations in the switch/sucrose nonfermenting BRG1‐associated factors complex. Patients are typically males in their fifth decade with a history of smoking who present with rapidly progressive intrathoracic disease and follow an aggressive clinical course. Metastatic disease is reported in up to 77% of cases; however, to our knowledge, cutaneous metastasis has not been reported nor has it been reported as the initial manifestation of the disease. Recognizing SMARCA4‐DTS from other types of epithelioid tumors that involve the skin is clinically relevant, as targeted therapies for SMARC‐deficient tumors are currently being investigated and early clinical trial data show therapeutic benefit.

This publication has 9 references indexed in Scilit: